A 2025 analysis by the Employers Health Coalition found that 64% of large employers (5,000+ employees) excluded GLP-1 medications for obesity from their health plans, citing projected costs of $12,000 to $15,000 per patient per year (Jain et al., Health Affairs 2025)
There may be evidence that similar benefits might extend to patients with SLE. Meanwhile, according to Drucker, there are multiple trials of GLP-1 receptor agonists underway in PsA and several other rheumatic conditions that are exacerbated in people with increased BMI
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial
(2021) demonstrated that escalating doses were well-tolerated in humans with no dose-limiting toxicities
User-Friendly Design: Convenient one-touch cap for easy daily use
With regular sessions, many patients experience significant improvements in skin texture, tone, and overall radiance, resulting in a more youthful, smoother complexion
